Literature DB >> 9529123

FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates.

C Lavagna-Sévenier1, S Marchetto, D Birnbaum, O Rosnet.   

Abstract

Proliferation and survival of hematopoietic progenitors are partially dependent on the interaction between the FLT3 receptor tyrosine kinase (RTK) and its ligand, FL. This biological function depends primarily on tyrosine phosphorylation of cellular targets that initiate several transduction cascades. These events return to their basal levels upon activation of specific phosphatases. We analyzed tyrosine phosphorylation events in response to FL, in human cell lines of different hematopoietic origins that express endogenous FLT3, namely the myelomonocytic, monocytic, pre-B and pro-B lineages. This study aimed at determining (1) the identity of FLT3 downstream substrates in physiologically relevant cells and (2) distinct substrate involvement in myeloid or early B cells. The two prominent tyrosine-phosphorylated proteins are p52SHC and p115CBL in myeloid cell lines and p52SHC and an uncharacterized p115 in early B cell lines. Following FL stimulation, a concomitant increase in both CBL phosphorylation and complex formation with p85 subunit of phosphatidylinositol 3' kinase is observed. In contrast, the GRB2/CBL association observed in unstimulated cells is not modified after stimulation, and SHC is never detected in anti-CBL immunoprecipitates. FL-inducible binding of CBL to the CRKII adaptor molecule is also demonstrated. This study presents a picture of the signaling events triggered by activation of endogenous FLT3 receptor in human hematopoietic cells, including the existence of a B cell-specific FLT3 substrate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9529123     DOI: 10.1038/sj.leu.2400921

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  28 in total

1.  Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.

Authors:  Jennifer L Rocnik; Rachel Okabe; Jin-Chen Yu; Benjamin H Lee; Neill Giese; David P Schenkein; D Gary Gilliland
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

2.  Transcriptome dynamics during human erythroid differentiation and development.

Authors:  Yadong Yang; Hai Wang; Kai-Hsin Chang; Hongzhu Qu; Zhaojun Zhang; Qian Xiong; Heyuan Qi; Peng Cui; Qiang Lin; Xiuyan Ruan; Yaran Yang; Yajuan Li; Chang Shu; Quanzhen Li; Edward K Wakeland; Jiangwei Yan; Songnian Hu; Xiangdong Fang
Journal:  Genomics       Date:  2013-10-08       Impact factor: 5.736

3.  RNA binding protein MSI2 positively regulates FLT3 expression in myeloid leukemia.

Authors:  Ayuna Hattori; Daniel McSkimming; Natarajan Kannan; Takahiro Ito
Journal:  Leuk Res       Date:  2017-01-11       Impact factor: 3.156

4.  Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.

Authors:  Obdulio Piloto; Melissa Wright; Patrick Brown; Kyu-Tae Kim; Mark Levis; Donald Small
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

Review 5.  Excessive Reactive Oxygen Species and Exotic DNA Lesions as an Exploitable Liability.

Authors:  Safnas F AbdulSalam; Fathima Shazna Thowfeik; Edward J Merino
Journal:  Biochemistry       Date:  2016-09-13       Impact factor: 3.162

6.  Treatment of FLT3-ITD acute myeloid leukemia.

Authors:  Amir T Fathi; Yi-Bin Chen
Journal:  Am J Blood Res       Date:  2011-09-09

7.  Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease.

Authors:  Katharine A Whartenby; Peter A Calabresi; Erin McCadden; Bao Nguyen; David Kardian; Tianhong Wang; Claudio Mosse; Drew M Pardoll; Donald Small
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-04       Impact factor: 11.205

Review 8.  Signal transduction of oncogenic Flt3.

Authors:  Chunaram Choudhary; Carsten Müller-Tidow; Wolfgang E Berdel; Hubert Serve
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

Review 9.  Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Authors:  Keith Pratz; Mark Levis
Journal:  Leuk Lymphoma       Date:  2008-05

10.  Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP).

Authors:  David B Rosen; Mark D Minden; Steven M Kornblau; Aileen Cohen; Urte Gayko; Santosh Putta; John Woronicz; Erik Evensen; Wendy J Fantl; Alessandra Cesano
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.